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Glucose-Insulin-Potassium Therapy Guided 
by a Glucose-Controlled Insulin Infusion System 
in Acute Myocardial Infarction 
G . M Ü L L E R - E S C H , P . B A L L , U . BEKEMEYER, H . DJONLAGIC, A . H A U P T M A N N , 
Κ . HEIDBÜCHEL, A . PETERS, R . TYBUSSEK, W . G . W O O D , and P . C. SCRIBA 
A number of hormonal and metabolic alterations have been observed during acute 
myocardial infarction ( A M I ) : There is a rapid increase of catecholamine and Cortisol 
secretion; free fatty acid (FFA) serum levels are markedly elevated (Gupta et al. 
1969; Januszewicz et al. 1971; Vetter et al. 1974); and insulin secretion may be 
inappropiately low. These alterations result in a disturbance of glucose utilization, so-
called stress hyperglycemia. Moreover, under these conditions and due to the 
accumulation of free fatty acids in the ischemic myocardium, severe ventricular 
arrhythmias as well as a progression of myocardial cell damage are likely to occur 
(Kurien and Oliver 1970; Kurien et al. 1971; Oliver et al. 1968). 
Glucose-insulin-potassium infusions (GIK) in A M I have been used in a number of 
clinical trials in order to overcome these deleterious effects (Mantle et al. 1981; 
Rogers et al. 1976,1979; Sodi-Palleres et al. (1962)). Some of the postulated benefits 
of GIK treatment in A M I are: a decrease of FFA, a reduction of potassium efflux, a 
repletion of intracellular potassium stores, an enhancement of myocardial glucose 
utilization, a reduction of myocardial oxygen consumption, and an improvement in 
coronary perfusion. These changes should reduce severe life-threatening arrhyth-
mias, limit infarct size, improve left ventricular function, and reduce hospital mortal-
ity (von Arnim and Bolte 1980; Brachfeld 1973; Kurien et al. 1971; Manke et al. 1981; 
Oliver 1973). With an "open loop" fixed GIK regime as in the studies mentioned 
above, severe hyperglycemia as well as hypoglycemia were not infrequently seen, 
because the degree of impairment of the insulin sensitivity could not be predicted. We 
therefore decided to use a glucose - controlled insulin infusion system (GCIIS); this 
involves applying "closed-loop" control during treatment with GIK according to the 
individual insulin sensitivity and thereby studying hormonal and metabolic patterns in 
A M I . 
Methods 
Nine patients (eight male, one female; age 61.8 ± 8.8 years) with A M I admitted to our 
intensive care unit within 12 h after onset of chest pain received GIK for 24 h. The 
solution contained 430 g glucose, 166 U porcine regular insulin, and 133 mEq KCl per 
liter. The infusion rate was 0.9 ml/kg/h. Additional feedback - controlled insulin and/ 
or glucose was given by the GCIIS (Biostator-Controller). The following constants 
were chosen: Mode 3:1, Var 100, BI80, BD 60, and FI 500-1000. Insulin concentra-
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tion of the GIK solution was increased when blood glucose could not be kept below 
250 mg/dl. Insulin, C-peptide, Cortisol, GH, prolactin, and lactate were determined at 
6-h intervals. FFAs were measured by gas-liquid chromatography (Tserng et al. 
1981). Figure 1 shows a schematic diagram of the technical equipment. The patient is 
connected to the GCIIS. By means of an interface all data for blood glucose (BG), 
insulin infusion rate ( IR), and dextrose infusion rate (DR) are transferred directly 
from the Biostator to a microcomputer for further processing (Muller-Esch et al. 
1984). The microcomputer fulfils several functions: 
1. Monitoring: BG, IR, and DR are plotted continuously 
2. Manual input: comments concerning, for example, the actual therapy can be 
entered via the keyboard 
3. Calculations: a BASIC computer program has been developed for the calculation 
of the glycemic indices mean blood glucose (MBG), M-value, and M A G E (Mul-
ler-Esch et al. 1984) 
4. Printer and floppy disks: all values for BG, IR, and DR, as well as comments which 
appear in their time - related positions, and calculated parameters are plotted and 
documented on 5-in. floppy disks. 
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Results 
The insulin sensitivity - as measured by blood glucose concentrations and total insulin 
requirements during GIK - varied markedly. Figure 2 a is an example from a patient 
with high insulin requirements. Initial BG is about 110 mg/dl, rising to more than 250 
mg/dl after starting GIK infusion. Despite submaximal additional feedback-control-
led insulin by the GCIIS, BG did not fall below 200 mg/dl. In contrast, in the patient 
shown in Fig. 2b, euglycemia during GIK could be obtained with only minor addi-
tional feedback-controlled insulin administration. And in another patient, additional 
feedback-controlled dextrose had to be given to prevent hypoglycemia during GIK, 
MBG being in the range of about 80 mg/dl (Fig. 2c). 
According to these data we can divide our patients into two groups: in five patients 
(group A ) , a total of 309 ± 52 U insulin/24 h was sufficient to maintain fair glycemic 
control (Table 1, top). In four patients, however (group B), insulin concentration of 
GIK had to be partially multiplied because of marked hyperglycemia: insulin require-
ments were 1193 ± 258 U/24 h; despite this, we did not achieve nearly normal BG 
values or nearly normal glycemic indices (Table 1, bottom). 
When compared to the "low insulin" group, the "high insulin" group presented with 
higher serum insulin levels before GIK treatment. During therapy, this group had 
higher values for C-peptide, Cortisol, prolactin, and lactate. GH and glucagon did not 
differ significantly (Table 1). 
Table 1. Insulin, C-peptide, glucagon, Cortisol, GH, prolactin, and lactate serum levels during 
GCIIS-guided GIK therapy in patients with low insulin requirements (group A) and high insulin 
requirements (group B). The glycemic indices MBG, MAGE, and M-value are also shown. (P < 0.05 
vs. group A) 
Group A (309 ± 52 U insulin/24 h, η = 5) 
Oh 6h 12 h 18 h 24 h 
Insulin (mU/1) 11.3 ± 7 . 5 191 ± 48 227 ± 181 289 ± 198 316 ± 219 
C-peptide fag/l) 2.6 ± 1.8 1.0 ± 0 . 7 0.6 ± 0.5 2.5 ± 4 . 1 2.1 ± 2 . 5 
Glucagon (ng/l) 140 ± 25 158 ± 53 160 ± 84 176 ± 82 164 ± 74 
Cortisol (ng/ml) 233 ± 131 172 ± 98 196 ± 95 212 ± 112 188 ± 92 
GH (ng/ml) 2.1 ± 1.5 4.4 ± 2.9 4.2 ± 2.0 3.5 ± 2 . 5 2.1 ± 1.6 
Prolactin (uU/ml) 398 ± 131 258 ± 64 242 ± 72 225 ± 79 248 ± 51 
Lactate (mmol/1) 1.4 ± 0 . 5 2.0 + 1.0 1.6 ± 0.8 1.3 ± 0 . 6 1.1 ± 0 . 3 
MBG: 94 ± 28 MAGE: 51 ± 8 Μ -value: 17 ± 7 
Group Β (1193 ± 258 U insulinl24 h, η = 4) 
Oh 6h 12 h 18 h 24 h 
Insulin (mU/1) • 43 ± 22 • >500 • >500 • >500 • >500 
C-peptide (yugfl) 8.0 ± 7.5 • 13.4 ± 12.9 • 15.0 ± 14.3 21.6 ±22.9 12.3 ± 15.6 
Glucagon (ng/l) 152 ± 77 87 ± 6 2 90 ± 7 3 124 ± 140 15.1 ± 169 
Cortisol (ng/ml) 301 ± 224 • 418 ± 135 • 418 ± 174 • 412 ± 203 • 418 + 186 
GH (ng/ml) 3.1 ± 2.4 6.1 ± 2 . 4 3.0 ± 1.8 1.7 + 1.4 1.5 ± 1.2 
Prolactin (μυ/ml) 590 ± 281 • 549 ± 182 • 489 ± 150 • 532 ± 135 • 681 ± 191 
Lactate (mmol/1) • 2.7 ± 1.3 • 3.5 ± 0 . 8 2.7 ± 0.9 • 2.7 ± 1.2 • 3.5 ± 1.4 
• MBG: 234 ± 42 • MAGE: 159 ± 57 • M-value: 46 ± 15 
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Fig. 2a-c. Blood glucose (BG), insulin infusion rate (IR), and dextrose infusion rate (DR) during 
GCIIS-guided GIK therapy in three patients with A M I 
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Table 2. Insulin, C-peptide, glucagon, Cortisol, GH, prolactin, lactate, and blood glucose (BG) 
levels in seven conventionally treated patients with A M I as compared to four patients under GCIIS-
guided GIK therapy (group Β). · Ρ < 0.05 vs. controls) 
Controls (n = 7) 
Oh 6h 12 h 18 h 24 h 
Insulin (mU/1) 35 ± 17 18 ± 11 26 ± 2 4 26 ± 2 4 39 ± 3 4 
C-peptide ^g/ l) 5.4 ± 2.9 4.9 ± 3.3 4.7 ± 3 . 2 6.4 ± 3 . 3 8.6 ± 6.2 
Glucagon (ng/l) 323 ± 446 373 ± 537 348 ± 412 431 ± 497 443 ± 407 
Cortisol (ng/ml) 239 ± 145 266 ± 192 218 ± 108 247 ± 171 229 ± 163 
GH (ng/ml) 2.1 ± 3 . 1 2.9 ± 3.8 2.4 ± 2.7 3.3 ± 6.5 2.6 ± 2.6 
Prolactin (μυ/ml) 834 ± 895 445 ± 256 273 ± 106 228 ± 50 306 ± 74 
Lactate (mmol/1) 2.1 ± 2 . 1 2.1 ± 1.8 1.7 ± 1.1 1.4 ± 0 . 5 1.4 ± 0.4 
BG (mg/dl) 147 ± 38 157 ± 49 122 ± 23 144 ± 48 162 ± 72 
Group Β (1193 ± 258 U insulin/24 h, η = 4) 
Oh 6h 12 h 18 h 24 h 
Insulin (mU/1) 43 ± 2 2 >500 >500 >500 >500 
C-peptide ^g/l) 8.0 ± 7.5 13.4 ± 12.9 • 15.0 ± 14.3 21.6 ± 22.9 12.3 ± 15.6 
Glucagon (ng/l) 152 ± 77 87 ± 6 2 90 ± 7 3 124 ± 140 151 ± 169 
Cortisol (ng/ml) 301 ± 224 418 ± 135 • 418 ± 174 412 ± 203 418 ± 186 
GH (ng/ml) 3.1 ± 2 . 4 6.1 ± 2.4 3.0 ± 1.8 1.7 ± 1.4 1.5 ± 1.2 
Prolactin (μυ/ml) 590 ± 281 549 ± 182 • 489 ± 150 • 532 ± 135 • 681 ± 191 
Lactate (mmol/1) 2.7 ± 1.3 3.5 ± 0 . 8 2.7 ± 0 . 9 • 2.7 ± 1.2 • 3.5 ± 1.4 
MBG: 234 ± 42 MAGE: 159 ± 57 M-value: 46 ± 15 
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Fig. 3. Free fatty acids (FFA) during 
GCIIS-guided GIK therapy in two 
patients with A M I 
Seven conventionally, treated patients with A M I served as controls (Table 2). In 
comparison with these patients without GIK, group Β had higher serum levels for 
C-peptide, Cortisol, prolactin, and lactate. 
Serial FFA measurements in two patients show a decrease of FFA under G I K 
below the arrhythmia threshold (Oliver et al. 1968) of 1200 μηιοΐ/ΐ (Fig. 3). 
Discussion 
Because of the small number of patients we are not yet able to decide whether the 
observed hormonal-metabolic differences between the groups are directly correlated 
to the infarct size or wheter they reflect different systemic reactions, different hor­
monal-metabolic patterns, during A M I . 
In conclusion, these preliminary data indicate that the impairment of insulin 
sensitivity and glucose utilization during A M I varies markedly. FFA can be reduced 
below the arrhythmia threshold. Further studies should compare metabolic, hemody­
namic, and antiarrhythmogenic effects of GCIIS-guided GIK support in patients with 
A M I . 
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